Sutent Europska Unija - hrvatski - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Asikreba 12,5 mg tvrde kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

asikreba 12,5 mg tvrde kapsule

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - sunitinibmalat - kapsula, tvrda - 12,5 mg - urbroj: jedna kapsula sadrži sunitinibmalat koji odgovara 12,5 mg sunitiniba

Asikreba 25 mg tvrde kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

asikreba 25 mg tvrde kapsule

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - sunitinibmalat - kapsula, tvrda - 25 mg - urbroj: jedna kapsula sadrži sunitinibmalat koji odgovara 25 mg sunitiniba

Asikreba 37,5 mg tvrde kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

asikreba 37,5 mg tvrde kapsule

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - sunitinibmalat - kapsula, tvrda - 37,5 mg - urbroj: jedna kapsula sadrži sunitinibmalat koji odgovara 37,5 mg sunitiniba